Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Colorcon
AstraZeneca
Medtronic

Last Updated: January 31, 2023

Investigational Drug Information for INCB054828


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for INCB054828?

INCB054828 is an investigational drug.

There have been 16 clinical trials for INCB054828. The most recent clinical trial was a Phase 2 trial, which was initiated on June 3rd 2019.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and Academic and Community Cancer Research United.

There are four US patents protecting this investigational drug and one hundred and thirty-eight international patents.

Recent Clinical Trials for INCB054828
TitleSponsorPhase
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.Incyte CorporationPhase 2
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaNational Cancer Institute (NCI)Phase 1
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaAcademic and Community Cancer Research UnitedPhase 1

See all INCB054828 clinical trials

Clinical Trial Summary for INCB054828

Top disease conditions for INCB054828
Top clinical trial sponsors for INCB054828

See all INCB054828 clinical trials

US Patents for INCB054828

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB054828 See Plans and Pricing Substituted tricyclic compounds as FGFR inhibitors Incyte Corporation (Wilmington, DE) See Plans and Pricing
INCB054828 See Plans and Pricing Heterocyclic compounds as immunomodulators Incyte Corporation (Wilmington, DE) See Plans and Pricing
INCB054828 See Plans and Pricing Heterocyclic compounds as immunomodulators Incyte Corporation (Wilmington, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Colorcon
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.